Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, pretomanid (Dovprela®) cannot be endorsed for use within NHS Wales in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB). |
||
|
||
Medicine details |
||
| Medicine name | pretomanid (Dovprela®) | |
| Formulation | 200 mg tablet | |
| Reference number | 3342 | |
| Indication | In combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB) |
|
| Company | Mylan Pharmaceuticals | |
| BNF chapter | Infections | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 02/02/2021 | |